Hyundai Pharmaceutical Co., Ltd.

A004310

KR7004310009

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
3,800 ^KRW	-0.26%		+1.33%	-7.54%

2023	Tranche Update on Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 14, 2023.	CI
2023	Hyundai Pharmaceutical Co., Ltd.(KOSE:A004310) dropped from S&P Global BMI Index	CI

Tranche Update on Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 14, 2023.

October 16, 2023 at 02:16 am EDT

From July 14, 2023 to September 30, 2023, the company has repurchased 53,846 shares, representing 0.2% for KRW 217.67 million. With this, the company has completed the repurchase of 53,846 shares, representing 0.2% for KRW 217.67 million under the buyback announced on July 14, 2023.

Latest news about Hyundai Pharmaceutical Co., Ltd.

Tranche Update on Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 14, 2023.	23-10-16	CI
Hyundai Pharmaceutical Co., Ltd.(KOSE:A004310) dropped from S&P Global BMI Index	23-09-18	CI
Hyundai Pharmaceutical Co., Ltd. announces an Equity Buyback for KRW 3,000 million worth of its shares.	23-07-14	CI
Hyundai Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	23-07-13	CI
Tranche Update on Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 23, 2022.	23-06-22	CI
Tranche Update on Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 23, 2022.	23-06-22	CI
Tranche Update on Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 23, 2022.	23-06-22	CI
Tranche Update on Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 23, 2022.	23-06-22	CI
Tranche Update on Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 23, 2022.	23-06-22	CI
Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback announced on June 23, 2022, has expired with 968,118 shares, representing 3.50% for KRW 4,388.11 million.	23-06-21	CI
Hyundai Pharmaceutical Co., Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares.	22-06-23	CI
Hyundai Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	22-06-22	CI
Market Chatter: Hyundai Pharmaceutical Seeks Regulatory Approval to Market Abortion Pill in South Korea	21-07-07	MT
Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback announced on July 14, 2008, has expired.	21-04-07	CI
Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback announced on April 22, 2010, has expired.	21-04-07	CI
Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback announced on June 28, 2019, has expired.	21-04-07	CI
Hyundai Pharmaceutical Co., Ltd.(KOSE:A004310) added to S&P Global BMI Index	20-09-21	CI
Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback Plan Extended till June 25, 2021.	20-06-25	CI
Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback Plan Extended till April 16, 2021.	20-04-13	CI
Tranche Update on Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 28, 2019.	19-09-26	CI
Hyundai Pharmaceutical Co., Ltd.(KOSE:A004310) dropped from S&P Global BMI Index	19-09-23	CI
Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback Plan Extended till July 13, 2020.	19-07-11	CI
Hyundai Pharmaceutical Co., Ltd. announces an Equity Buyback for KRW 2,000 million worth of its shares.	19-06-28	CI
Hyundai Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	19-06-27	CI
Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback Plan Extended till April 17, 2020.	19-04-17	CI

Chart Hyundai Pharmaceutical Co., Ltd.

Duration

Period

More charts

Company Profile

HYUNDAI PHARMACEUTICAL CO.,LTD is a Korea-based company principally engaged in the manufacture and distribution of pharmaceuticals and beverages. The Company mainly provides two categories of products: pharmaceuticals, including ophthalmological tablets, clopidogrel bisulfate, mirtazapine tablets and others, which are applied in the treatment of depressive disorder, hypertension, hemostatics and others, as well as healthcare food products, including vitamin products, calcium supplements and others. It also provides dietary various beverages and medical equipment. The Company mainly distributes its products within domestic market. In addition, the Company also involves in the leasing business.

Sector

Pharmaceuticals

Calendar

2024-07-11 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
HYUNDAI PHARMACEUTICAL CO., LTD.	-7.54%	76.41M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.62%	43.34B
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B
SANDOZ GROUP AG	+10.86%	14.09B
CIPLA LIMITED	+13.07%	13.64B
ZYDUS LIFESCIENCES LIMITED	+37.46%	11.43B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.46%	5.22B

Generic Pharmaceuticals

Hyundai Pharmaceutical Co., Ltd.

Equities

A004310

KR7004310009

Pharmaceuticals

Tranche Update on Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 14, 2023.

Latest news about Hyundai Pharmaceutical Co., Ltd.

Chart Hyundai Pharmaceutical Co., Ltd.

Company Profile

Sector Generic Pharmaceuticals